Journal Citations
-
Etravirine and Rilpivirine drug resistance among HIV-1
subtype C infected Children failing non -nucleoside reverse transcriptase
inhibitor-based regimens in South India.
Saravanan S, Kausalya B, Gomathi S,
et al
AIDS Res Hum Retroviruses.
2016 Nov 21.
Abstract
-
Assessment of etravirine resistance in HIV-1-infected paediatric patients
using population and deep sequencing: final results of the PIANO study.
Tambuyzer L, Thys K, Hoogstoel A, et al
Antivir Ther. 2015 Nov 13
Abstract
-
Etravirine in treatment-experienced, HIV-1-infected children
and adolescents: 48-week safety, efficacy and resistance analysis of the
phase II PIANO study.
Tudor-Williams G, Cahn P, Chokephaibulkit K, et al
HIV
Med. 2014 Mar 3.
-
Single-dose pharmacokinetics of pediatric and adult
formulations of etravirine and swallowability of the 200-mg tablet: results
from three Phase 1 studies.
Kakuda TN, Berckmans C, De Smedt G, et al
Int J Clin Pharmacol Ther.
2013 Aug 7
Abstract
-
Prevalence and risk factors associated with
resistance-associated mutations to etravirine in a cohort of perinatally
HIV-infected children.
Contreras GA, Bell CS, Del Bianco
GP, et al
J Antimicrob Chemother. 2013 Jun 3
Abstract
-
The role of etravirine in the management of
treatment-experienced pediatric patients with HIV.
Osterholzer D.
HIV AIDS (Auckl). 2013 Apr 10;5:67-73.
Abstract
-
Etravirine: A Guide to Its Use in Treatment-Experienced
Pediatric Patients with HIV-1 Infection in the US.
Lyseng-Williamson KA.
Paediatr Drugs. 2012 Oct
1;14(5):345-50.
Abstract
-
Pharmacokinetics and short-term safety and tolerability of
etravirine in treatment-experienced HIV-1-infected
children and adolescents.
Königs C, Feiterna-Sperling C, Esposito S, et al
AIDS.
2011 Dec 7
Abstract
-
Etravirine-based highly active antiretroviral therapy in HIV-1-infected
paediatric patients.
Briz V, Palladino C, Navarro M,
et al
HIV Med. 2011 Mar 13. doi: 10.1111
Abstract
-
Safety and efficacy of
etravirine in HIV-1-infected, treatment-experienced children and adolescents:
PIANO 48-week results
G. Tudor-Williams, P. Cahn, K.
Chokephaibulkit
(XIX International AIDS Conference)
Abstract
-
Rilpivirine and
etravirine resistance among HIV-1 subtype C infected children failing
non-nucleoside reverse transcriptase inhibitor-based regimens in south India
S. Saravanan, M. Vidya, R. Kanto
(XIX International AIDS Conference)
Abstract
-
Outcomes of third-line
antiretroviral therapy containing darunavir, etravirine or raltegravir in Thai
children with HIV infection
J. Ananworanich,, W. Prasitsuebsai, P.
Kosalaraksa, et al
(XIX International AIDS Conference)
Abstract
-
Bioavailability of the 100mg etravirine tablet dispersed in water and of
the 25mg pediatric tablet formulation
M. Schöller-Gyüre, T.N. Kakuda, R.M. Van Solingen-Ristea, et al
(XVII International AIDS Conference)
Abstract
-
Etravirine Pharmacokinetics in HIV-Infected Pregnant Women.
Mulligan N, Schalkwijk S, Best BM,
et al
Front Pharmacol. 2016
Aug 4;7:239.
-
Pharmacokinetics of Total and Unbound Etravirine in
HIV-1-Infected Pregnant Women.
Ramgopal M, Osiyemi O, Zorrilla C,
et al
J
Acquir Immune Defic Syndr. 2016
May
6.
Abstract
-
Etravirine resistance mutations in HIV-infected pregnant
women.
Cecchini D, Zapiola I, Fernandez
Giuliano S, et al
HIV Med. 2013 Feb;14(2):125-6.
Abstract
-
Safety and pharmacokinetics of etravirine in pregnant HIV-1-infected women
Izurieta P, Kakuda T, Feys C, Witek J.
HIV Med. 2011 Apr;12(4):257-8.
Abstract
|
New
and Noteworthy
Journal
Citations
Database
of ARV Drug Interactions